Gene expression in oligodendroglial tumors

[1]  W. Mason,et al.  Low-grade oligodendroglioma: current treatments and future hopes. , 2009 .

[2]  Bernd W Scheithauer,et al.  The 2007 WHO Classification of Tumors of the Nervous System: Controversies in Surgical Neuropathology , 2008, Brain pathology.

[3]  Jean-Yves Delattre,et al.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2008, Molecular Cancer.

[4]  F. Gaillard.  Oligodendroglioma , 2008, Radiopaedia.org.

[5]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[6]  A. Iafrate,et al.  Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers , 2008, Journal of neuropathology and experimental neurology.

[7]  D. Atsma,et al.  Heterogeneity of gene expression profiles in head and neck cancer , 2007, Head & neck.

[8]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[9]  Y. Maehara,et al.  Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma , 2007, Oncology.

[10]  V. Dbalý,et al.  Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. , 2007, International journal of oncology.

[11]  J. Lindsey.  Dexamethasone-induced Ras-related protein 1 is a potential regulatory protein in B lymphocytes. , 2007, International immunology.

[12]  J. Nesland,et al.  Expression of seprase in effusions from patients with epithelial ovarian carcinoma. , 2007, Chinese medical journal.

[13]  E. Ross,et al.  Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer , 2007, Clinical Cancer Research.

[14]  J. Penninger,et al.  The Molecular Gatekeeper Dexras1 Sculpts the Photic Responsiveness of the Mammalian Circadian Clock , 2006, The Journal of Neuroscience.

[15]  K. Nishio,et al.  Identification of expressed genes characterizing long-term survival in malignant glioma patients , 2006, Oncogene.

[16]  G. Reifenberger,et al.  Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling , 2006, International journal of cancer.

[17]  S. Horvath,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2006, Oncogene.

[18]  Carol Walker,et al.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. , 2006, Brain : a journal of neurology.

[19]  Alan Mackay,et al.  The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis , 2006, Breast Cancer Research.

[20]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Warnke,et al.  Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors , 2006, Neurology.

[22]  Jord H A Nagel,et al.  Gene expression profiles associated with treatment response in oligodendrogliomas. , 2005, Cancer research.

[23]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[24]  P. Warnke,et al.  Molecular pathology and clinical characteristics of oligodendroglial neoplasms , 2005, Annals of neurology.

[25]  Paul S Mischel,et al.  Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. , 2005, Brain research. Molecular brain research.

[26]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Thomas Kelly,et al.  Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  J. Tilgner,et al.  Validation of Intraoperative Diagnoses Using Smear Preparations from Stereotactic Brain Biopsies: Intraoperative versus Final Diagnosis—Influence of Clinical Factors , 2005, Neurosurgery.

[29]  C. Hartmann,et al.  Pathology and molecular genetics of oligodendroglial tumors , 2004, Journal of Molecular Medicine.

[30]  F. Heppner,et al.  Gene expression profiling and subgroup identification of oligodendrogliomas , 2004, Oncogene.

[31]  K. Brown,et al.  The Ras-related protein AGS1/RASD1 suppresses cell growth , 2004, Oncogene.

[32]  Jin Ho Kim,et al.  Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. , 2004, International journal of radiation oncology, biology, physics.

[33]  P. Warnke,et al.  Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[35]  Purvesh Khatri,et al.  Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate , 2003, Nucleic Acids Res..

[36]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[37]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[38]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[39]  Shuichi Tsutsumi,et al.  Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p , 2002, Oncogene.

[40]  F. Baas,et al.  Expression and distribution of id helix‐loop‐helix proteins in human astrocytic tumors , 2002, Glia.

[41]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[42]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[43]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Watson,et al.  Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. , 2001, Cancer research.

[45]  N. Ohuchi,et al.  Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast , 2001, International journal of cancer.

[46]  H. Kostron,et al.  Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-α1) are strongly expressed in human gliomas , 2000, Acta Neuropathologica.

[47]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[48]  Takako Onishi,et al.  AMY‐1, a novel C‐MYC binding protein that stimulates transcription activity of C‐MYC , 1998, Genes to cells : devoted to molecular & cellular mechanisms.

[49]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Levin,et al.  Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. , 1980, Cancer treatment reports.

[51]  力丸 竜也.  Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma , 2008 .

[52]  A. Houghton,et al.  FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. , 2004, Oncogene.